A5032747806- CAR-T cell therapy research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Animal Virus Infections Studies
- Bacillus and Francisella bacterial research
- vaccines and immunoinformatics approaches
- RNA Interference and Gene Delivery
- Immune Cell Function and Interaction
- Long-Term Effects of COVID-19
Singapore Immunology Network
2020-2022
Agency for Science, Technology and Research
2020-2022
Addgene
2020
The immune responses and mechanisms limiting symptom progression in asymptomatic cases of SARS-CoV-2 infection remain unclear. We comprehensively characterized transcriptomic profiles, cytokine responses, neutralization capacity antibodies, cellular phenotypes patients with acute to identify potential protective mechanisms. Compared symptomatic patients, had higher counts mature neutrophils lower proportion CD169+ expressing monocytes the peripheral blood. Systemic levels pro-inflammatory...
Abstract Acute myeloid leukemia (AML) is an aggressive disease with poor outcomes, overwhelmingly due to relapse. Minimal residual (MRD), defined as the persistence of leukemic cells after chemotherapy treatment, thought be major cause The origins relapse in AML have been traced rare therapy-resistant stem (LSCs) that are already present at diagnosis. Effective treatment strategies for long-term remission lacking, it has difficult eliminate LSCs conventional therapy. Here, we proposed a new...
Abstract The ongoing SARS-CoV-2 pandemic demands rapid identification of immunogenic targets for the design efficient vaccines and serological detection tools. In this report, using pools overlapping linear peptides functional assays, we present two immunodominant regions on spike glycoprotein that were highly recognized by neutralizing antibodies in sera COVID-19 convalescent patients. One is specific to SARS-CoV-2, other a potential pan-coronavirus target.
Abstract In vitro antibody selection against pathogens from naïve combinatorial libraries can yield various classes of antigen-specific binders that are distinct those evolved natural infection 1–4 . Also, rapid neutralizing discovery be made possible by a strategy selects for interfering with pathogen and host interaction 5 Here we report the antibodies neutralize SARS-CoV-2, virus responsible COVID-19 pandemic, highly diverse human Fab library. Lead 5A6 blocks receptor binding domain (RBD)...
The emergence of escape variants SARS-CoV-2 carrying mutations in the spike protein poses a challenge for therapeutic antibodies. Here, we show that through comprehensive engineering variable region neutralizing monoclonal antibody 5A6, engineered antibody, 5A6CCS1, is able to neutralize escaped neutralization by original 5A6 antibody. In addition improved affinity against variants, 5A6CCS1 was also optimized achieve high solubility and low viscosity, enabling concentration formulation...
StemPro Accutase Cell Dissociation Reagent: Gibco, A1110501 DMEM cell transfection medium: (high glucose, Hyclone, SH30022.01)+ 10% heat-inactivated FBS (Gibco) culture
<div>Abstract<p>Acute myeloid leukemia (AML) is an aggressive disease with poor outcomes, overwhelmingly due to relapse. Minimal residual (MRD), defined as the persistence of leukemic cells after chemotherapy treatment, thought be major cause The origins relapse in AML have been traced rare therapy-resistant stem (LSCs) that are already present at diagnosis. Effective treatment strategies for long-term remission lacking, it has difficult eliminate LSCs conventional therapy. Here,...
<p>Pathology report</p>
<p>Supplementary figures and methods.</p>
<div>Abstract<p>Acute myeloid leukemia (AML) is an aggressive disease with poor outcomes, overwhelmingly due to relapse. Minimal residual (MRD), defined as the persistence of leukemic cells after chemotherapy treatment, thought be major cause The origins relapse in AML have been traced rare therapy-resistant stem (LSCs) that are already present at diagnosis. Effective treatment strategies for long-term remission lacking, it has difficult eliminate LSCs conventional therapy. Here,...
<p>Pathology report</p>
<p>Supplementary figures and methods.</p>